Bitopertin is at least 4 years away from marketing approval, if it actually manages to traverse P2 and P3. Presuming it actually makes it that far, it won't get expedited review as there is a therapy already approved (Scenesse).
Ann: Appendix 4E and Annual Report 2022, page-19
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$10.16 |
Change
-0.190(1.84%) |
Mkt cap ! $509.2M | |||
| Open | High | Low | Value | Volume |
| $10.35 | $10.44 | $10.15 | $621.4K | 60.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2039 | $10.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.17 | 124 | 1 |
View Market Depth
| Last trade - 16.13pm 04/07/2025 (20 minute delay) ? |
| CUV (ASX) Chart |